Various consortia and working groups, composed of professionals from industry, academia, and government institutions, have undertaken or are undertaking nonclinical work to qualify safety biomarkers of tissue injury and function. As this work has developed and voluntary data have been submitted to regulatory authorities, study practices have come under close scrutiny in an attempt to ensure that the best science is consistently being applied. One practice that has been discussed in a variety of venues is the process used to generate histopathology data as additional end points and/or correlates in these studies. Histopathologic evaluation plays a critical role in these biomarker studies, because microscopic demonstration of given cellular processes are commonly used as a reference standard to assess diagnostic performance of candidate new biomarkers using methods such as receiver operating characteristic (ROC) analyses. In this regard, it is acknowledged that pathologists should not perform the histopathologic evaluation with knowledge of the candidate biomarker data; however, it has been questioned whether pathologists should conduct the histopathology evaluation for these biomarker studies without knowledge of treatment or other study-related data (i.e., ''blinded'' evaluation).
Research pathologists, and especially the Society of Toxicologic Pathology (STP), have closely examined regulatory study histopathology practices (Crissman et al. 2004; Wandall, Hansson and Ruden 2007) . Recently, a set of Best Practices for the conduct of histopathology review within nonclinical safety studies was endorsed by the STP (Crissman et al. 2004) . Key elements of these Best Practices indicate that the study pathologist should be informed as follows: (1) have knowledge of the treatment group from which the sample was obtained; and (2) have complete knowledge of all available study-related data that are associated with the animal from which the tissue was obtained. As these practices have been employed successfully for decades in the context of regulatory toxicology studies designed to assess human safety of new chemical entities with complete regulatory acceptance, the rationale for following a different process for biomarker validation and qualification is unclear to these authors.
This informed type of analysis (described above) is often referred to as ''unblinded,'' because the study pathologist has knowledge of dose groups and other study-related data at the time that the review is being conducted. It is considered that ''unblinded'' evaluation is critical to discriminate treatment-related changes from background, especially when subtle treatment-related effects increase the incidence or severity of spontaneous background findings. As needed, the study pathologist may reexamine tissues using a procedure sometimes termed ''targeted masked'' evaluation. This procedure entails reexamination of selected or all treated dose groups, randomly combined with controls and without knowledge of animal or group identity, to determine whether a subtle or equivocal finding can be identified consistently from control tissues. This second evaluation is performed after the pathologist feels confident that each finding has been fully characterized, to ensure either that subtle findings are assessed for incidence and severity or that equivocal findings are assessed to discriminate a true change from spontaneous background (in an unbiased manner).
Further to the nonclinical safety study Best Practices endorsed by STP, a peer-review process is generally used as a method for quality assurance, in which a second pathologist can corroborate the interpretations of the study pathologist. This second evaluation is typically conducted in an ''unblinded'' fashion, as this evaluation is not meant to generate new data but rather to provide a second party evaluation of the interpretations and conclusions of the primary pathologist.
Taking into consideration all available historical data as well as current practices of histopathology data generation, the current authors were tasked by the Scientific and Regulatory Policy Committee of the STP to consider the development of either a Best Practices or a Points to Consider guideline for industry and regulators, with emphasis on histopathology practices related to biomarker qualification. Although the final document will not be available until later, we wished to present our preliminary opinion based on the aforementioned Best Practices (Crissman et al. 2004 ). The present authors recognize that histopathology is a special discipline in which considerations for best practices may differ from those of other disciplines used in biomarker evaluation. The present authors also acknowledge that some toxicities are either unique to humans or idiosyncratic in nature and thus undetectable in standard nonclinical studies. Therefore, the method of evaluating slides would not affect the sensitivity for detection of such changes. Conversely, the present authors agree that ''unblinded'' slide evaluation creates a high degree of fidelity and consistency in the ability to identify animal toxicities. We concur with many previous reports (Crissman et al. 2004; Dodd 1988; Iatropoulos 1984; Prasse et al. 1986; Roe 1988; Weinburger 1979) that ''unblinded'' slide evaluation supplemented by ''targeted masked'' evaluation (if needed) is the most appropriate way to accurately discriminate ''true'' from ''false,'' or ''toxicity-related'' from ''normal biological variation or spontaneous background'' findings, and thus to discriminate a positive or negative correlation from a change in other parameters being evaluated. As this is also a critical objective of histopathology evaluation in biomarker qualification studies, an analogous approach is envisioned. Additionally, biomarker studies must account for significant spontaneous changes that could affect biomarker values. An ''unblinded'' evaluation does not detract from this objective, as the impact of spontaneous background changes are captured in the biologic variability of the biomarker values of the control group. It is also important to note that the agreed upon practice followed by consortia conducting biomarker qualification studies mandates blinding of the study pathologist to the candidate biomarker data.
Given the strong historical performance of these Best Practices in their application to regulatory-compliant, nonclinical safety studies, it is the opinion of the current authors that these Best Practices, specifically ''unblinded'' and ''targeted masked'' histopathology evaluation, are appropriate for the conduct of nonclinical safety biomarker qualification studies. In the recent debate over biomarker study histopathology practices, some have suggested that prospective studies to quantify the differences between ''blinded'' and ''unblinded'' evaluation should be conducted. We, however, question the value of conducting such studies, given that inherently, they would be difficult to design, execute, and interpret. A prominent treatment-related finding often will be outside the parameters of normal histology and will itself inform a ''blinded'' evaluator as to treatment group identity, thus rendering the blinding exercise ineffective. Additionally, a subtle treatment-related finding would potentially not be detected using blinded evaluation. However, such a finding will be discriminated using an ''unblinded'' followed by a ''targeted masked'' evaluation, because this is a sensitive qualitative method that avoids spurious interpretation resulting from diagnostic drift. As inquisitive scientists, however, we are not opposed to the conduct of such prospective studies, provided that the studies are appropriately designed, with rigorous input from experts in multiple disciplines.
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